SCHEMBL29879481

SCHEMBL29879481

C=Cc1nccc(CO)n1

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.39
SORD Q00796 1/20 0.31
RECQL P46063 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24738820 1.00 CCR1 (0.39) CCR1SORDRECQL
SCHEMBL9070196 0.80 CYP1A2 (0.33) SORD
SCHEMBL18061179 0.80
SCHEMBL20381536 0.76 GAA (0.32)
SCHEMBL23795894 0.74 NPSR1 (0.37)
SCHEMBL17898221 0.72 KCNH2 (0.56)
SCHEMBL4263702 0.70 SORD (0.52) CCR1SORDRECQL
SCHEMBL872419 0.70 HDAC8 (0.33)
SCHEMBL3606048 0.70
SCHEMBL15577831 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4308230-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2024-01-24 EP disclosed
WO-2022197758-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 WO disclosed